Do Glucagon-Like Peptide-1 Analogs Affect Diabetic Compliance and Quality of Life?

The major difficulties with diabetic treatment root in self-management, patient tolerance, and compliance with treatments. A new medication class, glucagon-like peptide-1 (GLP-1) analogs, has evidence of combining weight loss and glucose control with minimal side effects and cardiovascular benefit. For years, the standard therapy was adding insulin for patients with suboptimal response to oral agents. This method takes advanced education and lifestyle modifications to elicit adequate response. New injectable options allow initiation of a simpler regimen. The focus of this systematic review is to evaluate available evidence about the effect of GLP-1 analog therapy on patient compliance and quality of life.